| abstract |
PAD4 inhibitor compounds, compositions thereof and methods for treating disorders related to PAD4. Claim 1: A compound characterized by the formula (1), or a salt thereof pharmaceutically acceptable, wherein: ring A is a compound selected from the group of formulas (2), wherein ring A is optionally substituted with 1-4 selected groups of fluorine, -CN, -OR or aliphatic C₁₋₆ optionally substituted with 1-3 fluorine atoms; Ring B is a 5-6 membered heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen or sulfur; R¹ is hydrogen, -Cy or aliphatic C₁₋₆ optionally substituted with -Cy and also optionally substituted with 1-4 selected groups of fluorine, -CN or -OR; each -Cy is independently a 6-membered aryl ring containing 0-2 nitrogen atoms or a saturated 4-7 membered monocyclic ring having 0-2 heteroatoms independently selected from nitrogen, oxygen or sulfur, wherein -Cy is substituted optionally with 1-4 selected groups of fluorine, -CN or -OR; R² is hydrogen, -CN, -OR, -Cy or aliphatic C₁₋₁₀ optionally substituted with -Cy and also optionally substituted with 1-5 selected groups of fluorine, -CN or -OR; or: two R² groups on the same carbon are optionally taken together to form = O; n is 1, 2 or 3; X¹ is N or C (R³); R³ is -R, halogen or -OR; each R is independently hydrogen or aliphatic C₁₋₆ optionally substituted with 1-3 fluorine atoms; L is selected from a covalent bond or a linear or branched saturated or unsaturated hydrocarbon chain of C₁₋₆ members, wherein a methylene unit of L is optionally replaced by -S (O) ₂- or -C (O) N ( Rʸ) -, where Rʸ is R or - CH₂-phenyl; and R⁴ is halogen, R, phenyl or a 5-6 membered heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen or sulfur, wherein R⁴ is optionally substituted with 1-4 groups independently selected from halogen, -CN , -OR, -C (O) OH or aliphatic C₁₋₆ optionally substituted with 1-3 fluorine atoms. |